Novavax (NASDAQ: NVAX) has found hitting target dates for regulatory filings is easier said than done. The company delayed its planned submissions for Emergency Use Authorization for COVID-19 vaccine NVX-CoV2373 earlier this year. In this Motley Fool Live video recorded on Sept. 15, Motley Fool contributors Keith Speights and Brian Orelli talk about whether Novavax could experience further delays and what it might mean for the stock.
Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting